Egetis Therapeutics Agrees to Sell Priority Review Voucher for USD 190 Million
The agreement is a material corporate transaction, though the wire provides no further terms.
Related stories
Novo Nordisk Rises as Q3 Wegovy Pill Sales, Profit Beat Forecasts
M impact | EQUITY | Nov 04, 2026, 08:38 AM UTC
HL D&I Halla Q3 Operating Profit Rises 18% to 30 Billion Won
M impact | EQUITY | Nov 04, 2026, 08:24 AM UTC
BMW Expands Debrecen Plant to Three Shifts
BMW is adding a third shift at its Debrecen plant to meet demand for electric vehicles.
M impact | EQUITY | Nov 04, 2026, 08:24 AM UTC
Dollar Retreats as Democratic Midterm Wins Stoke AI Regulation Jitters
The dollar fell after Democratic victories in the U.S. midterm elections, as investors weighed the prospect of tighter AI regulation and its potential drag on economic growth.
M impact | FX | Nov 04, 2026, 08:24 AM UTC
Capacite Infraprojects Receives ₹3.06 Billion Letter of Award From Puravankara
M impact | EQUITY | Nov 04, 2026, 08:23 AM UTC
Capacite Infraprojects Wins 3.06 Billion-Rupee Award
Capacite Infraprojects received a letter of award worth 3.06 billion rupees from Puravankara.
M impact | EQUITY | Nov 04, 2026, 08:23 AM UTC